{"preliminary_commentary":{"by_channel":{"x_thread":21,"podcast":3,"x_video":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT01405079\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"ADJUVANT","nct_id":"NCT01405079","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=adjuvant-nct01405079. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ADJUVANT","arms":[{"description":"Gefitinib 250 mg/day oral daily","label":"Gefitinib","type":"EXPERIMENTAL"},{"description":"Vinorelbine 25 mg/m2 intravenous infusion on day 1 and day 8, Cisplatin 75 mg/m2 on day 1 for 4 cycles","label":"Vinorelbine+Cisplatin","type":"ACTIVE_COMPARATOR"}],"collaborators":["Guangdong Provincial People's Hospital","First Affiliated Hospital, Sun Yat-Sen University","Sun Yat-sen University","Jilin Provincial Tumor Hospital","Liaoning Cancer Hospital & Institute","First Hospital of China Medical University","Chinese PLA General Hospital","Peking Union Medical College Hospital","Peking University People's Hospital","Beijing Chest Hospital","309th Hospital of Chinese People's Liberation Army","Peking University Cancer Hospital & Institute","Peking University First Hospital","Tianjin Medical University Cancer Institute and Hospital","The Affiliated Hospital of Qingdao University","Jiangsu Cancer Institute & Hospital","The First Affiliated Hospital of Soochow University","Fudan University","Shanghai Pulmonary Hospital, Shanghai, China","Zhejiang Cancer Hospital","Zhejiang University","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Tongji Hospital","West China Hospital","Tang-Du Hospital"],"completion_date":{"date":"2020-12","type":"ESTIMATED"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":222,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Gefitinib","otherNames":["Iressa"],"type":"DRUG"},{"name":"Vinorelbine+Cisplatin","otherNames":[],"type":"DRUG"}],"last_update":"2020-02-18","lead_sponsor":"Guangdong Association of Clinical Trials","official_title":"A Randomized, Open-label Trial of Gefitinib Versus Combination of Vinorelbine Plus Platinum as Adjuvant Treatment in Pathological Stage II-IIIA(N1-N2) Non-small Cell Lung Cancer With EGFR Mutation","overall_status":"UNKNOWN","phases":["PHASE3"],"primary_completion_date":{"date":"2017-03","type":"ACTUAL"},"primary_outcomes":[{"measure":"Disease free survival","timeFrame":"Pts after surgery will receive long-term follow-up including chest CT scan, abdominal ultrasound every 3 months, brain MRI every 6 months, bone scan every 12 months for up to 3 years. The survival after 3 years will be followed up with telephone."}],"references":[{"citation":"Janjigian YY, Park BJ, Zakowski MF, Ladanyi M, Pao W, D'Angelo SP, Kris MG, Shen R, Zheng J, Azzoli CG. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. J Thorac Oncol. 2011 Mar;6(3):569-75. doi: 10.1097/JTO.0b013e318202bffe.","pmid":"21150674","type":"BACKGROUND"},{"citation":"Occhipinti M, Imbimbo M, Ferrara R, Simeon V, Fiscon G, Marchal C, Skoetz N, Viscardi G. Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation. Cochrane Database Syst Rev. 2025 May 27;5(5):CD015140. doi: 10.1002/14651858.CD015140.pub2.","pmid":"40421698","type":"DERIVED"},{"citation":"Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Wei YC, Liu YY, Chen C, Cheng Y, Yin R, Yang F, Ren SX, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT, Yang JJ, Yan HH, Yang XN, Liu SY, Zhou Q, Wu YL. Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial. J Clin Oncol. 2021 Mar 1;39(7):713-722. doi: 10.1200/JCO.20.01820. Epub 2020 Dec 17.","pmid":"33332190","type":"DERIVED"},{"citation":"Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, Liu YY, Chen C, Cheng Y, Xu L, Wang J, Fei K, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT, Yan HH, Yang XN, Zhou Q, Wu YL; ADJUVANT investigators. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 2018 Jan;19(1):139-148. doi: 10.1016/S1470-2045(17)30729-5. Epub 2017 Nov 21.","pmid":"29174310","type":"DERIVED"}],"start_date":{"date":"2011-09-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation","url":"https://clinicaltrials.gov/study/NCT01405079"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/adjuvant-nct01405079"}